Surrozen, Inc./DE Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Surrozen, Inc./DE (SRZN) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $300.00 thousand for the 1-month period ending 2021-09-30, per its 10-K filed 2022-03-28.
Discontinued › Notes
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-03-28
- Surrozen, Inc./DE right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- Surrozen, Inc./DE right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $563.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 1 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2021-09-30 | $300.00K 10-K · filed 2022-03-28 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $563.00K 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $563.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |